Intravenous immunoglobulin for myasthenia gravis

重症肌无力 医学 安慰剂 恶化 神经肌肉疾病 荟萃分析 内科学 临床试验 抗体 不利影响 随机对照试验 自身免疫性疾病 科克伦图书馆 儿科 梅德林
作者
Philippe Gajdos,Sylvie Chevret,Klaus V. Toyka
出处
期刊:The Cochrane library [Elsevier]
被引量:201
标识
DOI:10.1002/14651858.cd002277.pub4
摘要

Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). This is an update of a review first published in 2003 and last updated in 2007.To examine the efficacy of IVIg for treating exacerbations of myasthenia gravis or for chronic myasthenia gravis.We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 October 2011), CENTRAL (2011, Issue 3), MEDLINE (January 1966 to September 2011) and EMBASE (January 1980 to September 2011) using 'myasthenia gravis' and 'intravenous immunoglobulin' as the search terms.All randomised controlled trials (RCTs) or quasi-RCTs in which IVIg was compared with no treatment, placebo or plasma exchange, in people with myasthenia gravis.One review author extracted the data and two others checked these data. For methodological reasons, no formal meta-analysis was performed.We identified seven RCTs. These trials differ in inclusion criteria, comparison with alternative treatment and outcomes. In a trial comparing IVIg with placebo, including 51 participants with myasthenia gravis worsening, the mean difference (MD) in quantitative myasthenia gravis score (QMGS) (MD 95% CI) after 14 days was: -1.60 (95% CI - 3.23 to 0.03) this result being borderline statistically significant in favour of IVIg. In an unblinded study of 87 participants with exacerbation comparing IVIg and plasma exchange there was no difference in myasthenic muscle score (MMS) after 15 days (MD -1.00; 95% CI -7.72 to 5.72). In a study of 84 participants with worsening myasthenia gravis there was no difference in change in QMGS 14 days after IVIg or plasma exchange (MD -1.50; 95% CI -3.43 to 0.43). In a study of 12 participants with moderate or severe myasthenia gravis, which was at high risk of bias from skewed allocation, the mean fall in QMGS both for IVIg and plasma exchange after four weeks was significant (P < 0.05). A study with 15 participants with mild or moderate myasthenia gravis found no difference in change in QMGS 42 days after IVIg or placebo (MD 1.60; 95% CI -1.92 to 5.12). A study included 33 participants with moderate exacerbations of myasthenia gravis and showed no difference in change in QMGS 14 days after IVIg or methylprednisolone (MD -0.42; 95% CI -1.20 to 0.36). All these three smaller studies were underpowered. The last trial, including 168 people with exacerbations, showed no evidence of superiority of IVIg 2 g/kg over IVIg 1 g/kg on the change of MMS after 15 days (MD 3.84; 95% CI -0.98 to 8.66). Adverse events due to IVIg were moderate (fever, nausea, headache), self-limiting and subjectively less severe than with plasma exchange (although, given the available data, no statistical comparison was possible). Other than where specific limitations are mentioned the trials were generally at low risk of bias.In exacerbation of myasthenia gravis, one RCT of IVIg versus placebo showed some evidence of the efficacy of IVIg and two did not show a significant difference between IVIg and plasma exchange. Another showed no significant difference in efficacy between 1 g/kg and 2 g/kg of IVIg. A further, but underpowered, trial showed no significant difference between IVIg and oral methylprednisolone. In chronic myasthenia gravis, there is insufficient evidence from RCTs to determine whether IVIg is efficacious.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
CV16完成签到,获得积分10
1秒前
1秒前
2秒前
ocean完成签到,获得积分10
3秒前
天天开心完成签到,获得积分10
3秒前
jisoo发布了新的文献求助10
4秒前
Cbbaby发布了新的文献求助30
4秒前
Orange应助刀光凛凛采纳,获得30
4秒前
小黄完成签到 ,获得积分10
5秒前
5秒前
xiaoyu完成签到,获得积分10
6秒前
nqterysc完成签到,获得积分10
7秒前
无000发布了新的文献求助10
8秒前
繁荣的无招应助狼来了aas采纳,获得30
9秒前
9秒前
可爱冰绿完成签到,获得积分10
10秒前
瓦学弟的妈妈完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
11秒前
英吉利25发布了新的文献求助20
12秒前
TRIZ完成签到 ,获得积分10
14秒前
15秒前
16秒前
瓦学弟的妈妈关注了科研通微信公众号
17秒前
17秒前
18秒前
18秒前
19秒前
zhu发布了新的文献求助10
20秒前
zyx发布了新的文献求助10
20秒前
21秒前
8R60d8应助令狐惜海采纳,获得10
21秒前
巴纳拉完成签到,获得积分10
22秒前
天天开心发布了新的文献求助10
24秒前
25秒前
彭于晏应助sui采纳,获得10
25秒前
奶牛在吃豆完成签到,获得积分10
29秒前
CodeCraft应助jj采纳,获得10
30秒前
30秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3958225
求助须知:如何正确求助?哪些是违规求助? 3504388
关于积分的说明 11118283
捐赠科研通 3235682
什么是DOI,文献DOI怎么找? 1788411
邀请新用户注册赠送积分活动 871211
科研通“疑难数据库(出版商)”最低求助积分说明 802565